SEARCH:   Advanced

Blood, 30 April 2009, Vol. 113, No. 18, pp. 4179-4187. Prepublished online as a Blood First Edition Paper on November 13, 2008; DOI 10.1182/blood-2008-07-172007. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-07-172007v1 113/18/4179    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Juliusson, G. Articles by Hoglund, M. Search for Related Content PubMed PubMed Citation Articles by Juliusson, G. Articles by Hoglund, M. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 30, 2008 Accepted November 2, 2008 Age and acute myeloid leukemia. Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Gunnar Juliusson*, Petar Antunovic, Asa Derolf, Soren Lehmann, Lars Mollgard, Dick Stockelberg, Ulf Tidefelt, Anders Wahlin, and Martin Hoglund Lund University Hospital, Lund, Sweden Linkoping University Hospital, Linkoping, Sweden Karolinska Institute, Stockholm, Sweden Karolinska Institute, Huddinge, Sweden Sahlgrenska University Hospital, Gothenburg, Sweden Orebro University Hospital, Orebro, Sweden Norrland University Hospital, Umea, Sweden Academic Hospital, Uppsala, Sweden * Corresponding author; email: gunnar.juliusson{at}med.lu.se. AML is most common in elderly, and most elderly are believed to be unfit for intensive treatment due to the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (non-APL) diagnosed 1997-2005 (n=2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission (CR) rates, and survival. Outcomes were strongly age and PS dependent. Early death rates were always lower with intensive therapy than with palliation only. Long-term survivors were found among elderly given intensive treatment despite poor initial PS. Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy. This analysis provides unique real world data from a large, complete and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly. Standard intensive treatment improves early death rates and long-term survival as compared to palliation, most AML patients up to 80 years should be considered fit for intensive therapy, and new therapies must be compared with standard induction. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Closer to the truth in AML Jacob M. Rowe Blood 2009 113: 4129-4130. [Full Text] [PDF] This article has been cited by other articles: J. M. Rowe Closer to the truth in AML Blood, April 30, 2009; 113(18): 4129 - 4130. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020